Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 7/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 8/20 | 0.40 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.40 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.39 |
| ▸ | CHRNG | P07510 | 2/20 | 0.39 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.39 |
| ▸ | CHRND | Q07001 | 2/20 | 0.39 |
| ▸ | FURIN | P09958 | 2/20 | 0.38 |
| ▸ | FAP | Q12884 | 3/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.37 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22138449 | 0.94 | SIRT1 (0.41) | SIRT1SIRT2SIRT3CHRNA1CHRNG | |
| SCHEMBL21153392 | 0.93 | SIRT2 (0.38) | SIRT1SIRT2SIRT3FURINFAP | |
| SCHEMBL23347154 | 0.93 | SIRT5 (0.38) | SIRT1SIRT2SIRT3FURINFAP | |
| SCHEMBL21152749 | 0.93 | FAP (0.41) | SIRT1SIRT2SIRT3FURINFAP | |
| SCHEMBL19915429 | 0.92 | SIRT1 (0.47) | SIRT1SIRT2SIRT3CHRNDFURIN | |
| SCHEMBL27277777 | 0.92 | SIRT5 (0.39) | SIRT1SIRT2SIRT3FURINFAP | |
| SCHEMBL22138371 | 0.92 | FURIN (0.44) | SIRT1SIRT2CHRNA1CHRNGCHRNB1 | |
| SCHEMBL22702531 | 0.91 | FURIN (0.38) | SIRT1SIRT2SIRT3FURINFAP | |
| SCHEMBL24349418 | 0.91 | FURIN (0.38) | SIRT1SIRT2SIRT3FURINFAP | |
| SCHEMBL27043902 | 0.91 | FURIN (0.38) | SIRT1SIRT2SIRT3FURINFAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11541126-B1 | Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereof | SILVERBACK THERAPEUTICS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11541126-B1 | Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereof | ASGR1, TLR8, HAVCR2 | SIRT1 2590/4885SIRT2 2353/4885SIRT3 3745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.